About Zentalis Pharmaceuticals, Inc.
https://zentalis.comZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
CEO
Julie M. Eastland
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Morgan Stanley
Equal Weight
Wells Fargo
Equal Weight
Wedbush
Neutral
UBS
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
MATRIX CAPITAL MANAGEMENT COMPANY, LP
Shares:13.96M
Value:$49M
BLACKROCK INC.
Shares:4.82M
Value:$16.91M
VANGUARD GROUP INC
Shares:2.9M
Value:$10.19M
Summary
Showing Top 3 of 119
About Zentalis Pharmaceuticals, Inc.
https://zentalis.comZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $33.73M ▼ | $-26.69M ▲ | 0% | $-0.37 | $-26.53M ▲ |
| Q2-2025 | $0 | $36.06M ▼ | $-26.87M ▲ | 0% | $-0.37 ▲ | $-34.75M ▲ |
| Q1-2025 | $0 ▼ | $45.62M ▼ | $-48.28M ▼ | 0% ▲ | $-0.67 | $-37.56M ▲ |
| Q4-2024 | $26.86M ▲ | $76.71M ▲ | $-47.47M ▼ | -176.71% ▼ | $-0.67 ▼ | $-45.8M ▲ |
| Q3-2024 | $0 | $51.43M | $-40.16M | 0% | $-0.56 | $-51.11M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $280.7M ▼ | $327.25M ▼ | $74.38M ▼ | $252.87M ▼ |
| Q2-2025 | $303.43M ▼ | $351.71M ▼ | $77.21M ▼ | $274.5M ▼ |
| Q1-2025 | $332.45M ▼ | $384.02M ▼ | $88.64M ▼ | $295.38M ▼ |
| Q4-2024 | $371.08M ▼ | $430.34M ▼ | $93.15M ▼ | $337.19M ▼ |
| Q3-2024 | $391.25M | $450.66M | $96.33M | $354.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-26.69M ▲ | $-26.96M ▲ | $28.32M ▼ | $115K ▲ | $1.47M ▲ | $-26.96M ▲ |
| Q2-2025 | $-26.87M ▲ | $-34.71M ▼ | $30.38M ▼ | $0 ▼ | $-4.33M ▼ | $-34.71M ▼ |
| Q1-2025 | $-48.28M ▼ | $-32.64M ▲ | $40.48M ▲ | $189K ▲ | $8.03M ▲ | $-32.64M ▲ |
| Q4-2024 | $-47.47M ▼ | $-39.7M ▲ | $32.28M ▼ | $0 ▼ | $-7.42M ▼ | $-39.7M ▲ |
| Q3-2024 | $-40.16M | $-44.05M | $48.24M | $92K | $4.34M | $-44.05M |
CEO
Julie M. Eastland
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Morgan Stanley
Equal Weight
Wells Fargo
Equal Weight
Wedbush
Neutral
UBS
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
MATRIX CAPITAL MANAGEMENT COMPANY, LP
Shares:13.96M
Value:$49M
BLACKROCK INC.
Shares:4.82M
Value:$16.91M
VANGUARD GROUP INC
Shares:2.9M
Value:$10.19M
Summary
Showing Top 3 of 119